JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267286

Human CRIM1 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CRIM1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 2 bp insertion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human CRIM1 knockout HEK-293T cell line (AB267286)
  • Sanger seq

Unknown

Sanger Sequencing - Human CRIM1 knockout HEK-293T cell line (AB267286)

Allele-2 : 2 bp insertion in exon 3.

Sanger Sequencing - Human CRIM1 knockout HEK-293T cell line (AB267286)
  • Sanger seq

Unknown

Sanger Sequencing - Human CRIM1 knockout HEK-293T cell line (AB267286)

Allele-1 : 1 bp deletion in exon3

Cell Culture - Human CRIM1 knockout HEK-293T cell line (AB267286)
  • Cell Culture

Unknown

Cell Culture - Human CRIM1 knockout HEK-293T cell line (AB267286)

Representative images of CRIM1 knockout HEK293T cells, low and high confluency examples (top left and right respectively) and wild-type HEK293T cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS M5000 microscope.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 2 bp insertion in exon 3

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267286-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB267286-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267286 Human CRIM1 knockout HEK-293T cell line", "number":"AB267286-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267286-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB267286-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267286 Human CRIM1 knockout HEK-293T cell line", "number":"AB267286-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267286-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267286 Human CRIM1 knockout HEK-293T cell line", "number":"AB267286-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267286-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267286 Human CRIM1 knockout HEK-293T cell line", "number":"AB267286-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CRIM1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CRIM1 also known as cysteine-rich motor neuron 1 protein has a molecular mass of around 110 kDa. As a transmembrane protein it localizes mainly to the endoplasmic reticulum. Researchers have detected its expression in various tissues including the retina kidneys brain and spinal cord. It contains a distinctive cysteine-rich motif and plays roles in cellular adhesion and growth factor regulation.
Biological function summary

The function of CRIM1 extends to the modulation of growth factor activity particularly by interacting with bone morphogenetic proteins (BMPs). This interaction suggests its potential involvement in developmental processes. Studies have indicated that CRIM1 might participate in forming protein complexes related to cell surface receptors influencing cell signaling pathways that govern growth and differentiation.

Pathways

CRIM1's involvement in BMP signaling and angiogenesis highlights its significance within these biological pathways. BMPs which are growth factors play a part in bone and cartilage development therefore CRIM1's regulatory action can affect these processes. Additionally CRIM1 interacts with proteins like noggin in the BMP pathway to modulate cellular responses to extracellular signals contributing to developmental and morphogenic outcomes.

CRIM1 links to congenital abnormalities and ocular disorders. Its known interaction with BMPs associates it with conditions like kidney dysplasia where the disruption of normal signaling can lead to organ malformations. In the context of eye development CRIM1's interaction with BMPs and noggin is important for retinal and lens development. Understanding CRIM1's role in these pathways could offer insights into therapeutic targets for congenital and degenerative diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com